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We recently tested serum from a human immunodeficiency virus-infected patient for the presence of
cryptococcal antigen using the Meridian latex agglutination (LA) test (Cryptococcal Antigen Latex Aggluti-
nation System). Two pronase-treated serum specimens from the patient had LA titers of 80 and 160, but the
patient had no evidence of cryptococcal disease. The serum was negative for rheumatoid factor, a well-
documented cause of false-positive LA reactions. Seven blood culture supernatants from the patient were also
LA positive, but were culture negative for cryptococcus. When the sera and blood culture supernatants were
treated with 0.01 M 2-13-mercaptoethanol (2-ME), the agglutinating activity was ablated. Similar results were
seen when the sera were tested by two other commercial LA assays. Serum and cerebrospinal fluid specimens
from patients with confirmed cryptococcal disease were treated with 2-ME, and the results were compared with
those obtained after pronase (sera) or heat (cerebrospinal fluid) inactivation. The titers were identical (n = 56)
or within 1 dilution (n = 3). One hundred serum specimens from human immunodeficiency virus-seropositive
patients with no known history of cryptococcal disease were examined to determine the frequency of
false-positive reactivity in this patient population. Of this group, three were positive following pronase
treatment. One remained positive after 2-ME treatment; the remaining two were negative. These data indicate
that 2-ME can be used to eliminate nonspecific reactivity in the LA test without affecting true-positive results.
Cryptococcus neoformans is a ubiquitous yeast capable of
causing disease in healthy as well as immunocompromised
hosts (28, 29). Cryptococcosis, the fourth most common op-
portunistic infection in AIDS patients (11, 23, 34), has a wide
spectrum of clinical presentations (22, 29). Therefore, testing
for this pathogen has become routine for patients infected with
human immunodeficiency virus (HIV). Although the rate of
culture positivity is high in this patient population (2-4),
growth and identification of the organism require several days.
Thus, the development of rapid diagnostic tests has had a great
impact on the management of cryptococcosis in HIV-infected
individuals.
First described in 1967 by Bloomfield et al. (4), the crypto-
coccal latex agglutination (LA) assay, a direct antigen detec-
tion methodology, is one of the most valuable serodiagnostic
tests for fungi performed on a routine basis (12, 17, 32).
False-positive LA reactions caused by a variety of interfering
factors have been eliminated by several procedural modifica-
tions, including specimen pretreatment and the incorporation
of control reagents (1, 10. 16, 19, 30, 32).
In this report we describe a false-positive cryptococcal
antigen LA test (LAT) result in an HIV-infected male who
presented with a pseudomonal rectal abscess. Several negative
fungal cultures and his rapid response to antibacterial therapy
alerted us to the possibility of a false-positive reaction. Further
investigation demonstrated that this cross-reactivity could be
eliminated by pretreatment with 2-,B-mercaptoethanol (2-ME).
This finding prompted an investigation of the incidence of the
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nonspecific reactivity of the cryptococcal LA assay in an
HIV-infected population of subjects.
MATERIALS AND METHODS
Case report. The patient, a 29-year-old male with HIV
infection secondary to severe hemophilia A, presented to the
emergency room with a history of fever and chills with night
sweats for the previous 6 months and a 3-day history of nausea
and vomiting. He had been discharged 3 days previously
following treatment for rectal bleeding secondary to a rectal
fissure. On admission, he-complained of rectal pain, had a
fever of 38.9°C, a leukocyte count of 1,000/mm3 with a CD4
count of 4/mm3 and a small amount of thrush. He was
dehydrated and somnolent. Otherwise, his physical examina-
tion was unremarkable. Since the cause of his illness was not
clear, the differential diagnosis was very broad. An assay for
cryptococcal antigen in serum was performed and was positive,
with a titer of 80. In response to that test, a computed
tomography scan of his head was done, and the result was
within normal limits. A cerebrospinal fluid (CSF) examination
revealed two leukocytes per ml, with 13% lymphocytes and
87% monocytes, and normal protein and glucose levels. CSF
culture and blood cultures (six sets) were all negative for
cryptococcus. The patient was begun on amphotericin B
therapy, which he tolerated poorly. He received a total of 341
mg of amphotericin B over the next 10 days. On the day after
the CSF examination, one of two blood cultures grew Pseudo-
monas aeruginosa. He received imipenem and an aminoglyco-
side and his fever defervesced within 24 h. Four subsequent
blood cultures were negative. Culture of a specimen from his
rectal fissure also grew P. aeruginosa. A repeat test for crypto-
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coccal antigen in serum was done 9 days after the original one;
the result was again positive, with a titer of 160.
Eight months later, he was admitted to the hospital with
cryptococcal meningitis. Lab results included a positive CSF
stain and culture, a cryptococcal antigen titer in serum of 400,
a CSF antigen titer of 200, and 2 weeks later, a repeat CSF
antigen titer of 80.
Patient specimens. A total of five specimens (three serum
and two CSF specimens) from the patient described in the case
report were submitted to the Clinical Microbiology and Immu-
nology Laboratory of the University of North Carolina Hospi-
tals for detection of cryptococcal antigen. Cryptococcal anti-
gen-positive sera and CSF were from patients for whom
specimens had been submitted for detection of antigen and
who were known to be culture positive. One hundred serum
specimens from HIV-positive patients with no clinical history
of cryptococcal disease (and negative cultures) were used to
determine the false-positive cryptococcal rates in this patient
population. Eight serum specimens positive for rheumatoid
factor were also examined for false-positive reactivity.
Cryptococcal antigen tests. (i) CALAS. Unless otherwise
noted, the cryptococcal antigen test used in the present study
was the Cryptococcal Antigen Latex Agglutination System
(CALAS; Meridian Diagnostics, Cincinnati, Ohio). The pro-
cedure was performed according to the manufacturer's instruc-
tions. All serum specimens were treated with pronase (15 min
at 56°C and then boiled for 5 min), and CSF specimens were
boiled (5 min) prior to testing. Tenfold serial dilutions of
screen-positive specimens were prepared in buffer solution. On
the basis of the results of this screening dilution, additional
twofold serial dilutions were prepared until the titer of the
specimen was determined to the endpoint.
(ii) CRYPTO-LEX. The CRYPTO-LEX System (Trinity
Laboratories, Inc., Raleigh, N.C.) was performed according to
the manufacturer's recommendations. CRYPTO-LEX is an
LAT in which latex particles are sensitized with a monoclonal
antibody which reacts with all four serotypes of C. neoformans.
A control latex reagent is not tested with this system since
these monoclonal antibodies do not react with rheumatoid
factor. Patient samples (serum and/or CSF) were heat treated
in a 56°C heat block for 15 min prior to testing. The titers of
positive specimens were determined as described above for
CALAS.
(iii) CRYPTO-LA test. The Crypto-LA test (Wampole Lab-
oratories, Cranbury, N.J.) was performed according to the
manufacturer's recommendations. Serum and CSF specimens
were heat inactivated in a 56°C water bath for 30 min prior to
testing.
PREMIER EIA. The Premier Cryptococcal Antigen enzyme
immunoassay EIA (Meridian Diagnostics) was performed as
described previously (13). All EIA screenings were performed
without specimen pretreatment.
2-ME treatment. Serum and CSF specimens that were
positive for cryptococcal antigen by CALAS LA assay were
treated with 0.01 M 2-ME (Sigma Chemical Co., St. Louis,
Mo.) as described previously (30). A 0.1 M solution of 2-ME in
phosphate-buffered saline (PBS) was made fresh daily and was
kept on ice until use. Two aliquots of 180 [LI of CSF or serum
which had been boiled (CSF) or treated with pronase and
boiled (serum) were placed into separate tubes. Twenty micro-
liters of PBS was added to the aliquot in one tube; 20 ,ul of 0.1
M 2-ME in PBS was added to the aliquot in the other tube.
Specimens were vortexed and incubated for I h at 35°C. Both
aliquots were examined for the presence of cryptococcal
antigen.
Rheumatoid factor. The RapiTex RF (Behring Diagnostics,




(mo-day-yr) type Untreated Treated with
2-ME
6-2-92 Serum 80 Negative
6-11-92 Serum 160 Negative
2-12-93 Serum 400 400
2-12-93 CSF 200 200
2-28-93 CSF 80 80
" Cryptococcal antigen titer obtained by using CALAS LA reagents.
Inc., Somerville, N.J.) was used for the detection of rheuma-
toid factor in serum. The LAT kit was used according to the
manufacturer's recommendations.
Blood cultures. Blood cultures were performed by using the
BacT-Alert blood culture system (Organon Teknika, Durham,
N.C.). Blood was inoculated into trypticase soy broth and was
monitored for 7 days. An aliquot of the blood-broth mixture
was removed from each of the bottles containing the blood of
the patient described in the case report at the termination of
the blood culture. The blood-broth mixture was centrifuged to
pellet all of the cells. Following pronase treatment, the super-
natant was assayed for agglutinating activity with the CALAS
LA reagents.
Absorption studies. Attempts were made to characterize the
false-positive reactivity via absorption of the interfering sub-
stance with P. aeruginosa and monoclonal antibodies.
(i) P. aeruginosa. The P. aeruginosa isolate from the patient
described above in the case report was subcultured from an
agar plate, inoculated into tryptic soy broth, and incubated
overnight at 35°C. A suspension of the overnight culture
equivalent to a no. 3 McFarland standard was prepared in
saline. Two hundred microliters of the patient's serum was
mixed with 200 ,ul of the P. aeruginosa suspension and was
rotated for 30 min at room temperature. This mixture was
centrifuged, and the supernatant was tested with the CALAS
LA reagents.
Monoclonal antibodies. Mouse monoclonal anti-cryptococ-
cal capsular polysaccharide antibodies were a gift from Bruce
Clinton (Trinity Laboratories, Inc.). These antibodies were the
same as those used to prepare the CRYPTO-LEX LA reagent.
Serum specimens from the patient described above in the case
report were mixed with equal volumes of 1:10, 1:100, 1:1,000,
and 1:10,000 dilutions of the monoclonal antibody. The mix-
tures were vortexed and incubated overnight at 4°C. The
specimens were centrifuged in a microcentrifuge (16,000 x g)
for 3 min, and the supernatant was assayed for reactivity with
the CRYPTO-LEX and CALAS LA reagents.
RESULTS
Table 1 summarizes cryptococcal LA assay results, both with
and without 2-ME treatment, for the case patient. Neither of
the two specimens tested in June 1992 was culture positive for
C. neoformans. Approximately 8 months later the patient did
develop culture-confirmed cryptococcal meningitis. At that
time, two CSF and one serum specimen were CALAS LA assay
positive following pronase or 2-ME treatment.
The serum specimen testing false positive was tested by the
three LA and the EIA cryptococcal antigen detection systems.
The LA assays gave similar results; the pronase-treated ali-
quots were positive, while the specimens treated with 2-ME
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Patient serum Positive (1:80) Negative
Blood culture supernatant" Positive (1:80) Negative
P. aeruginosa-positive blood culture Positive (1:80) Negative
supernatant
Uninoculated blood culture broth Equivocal Negative
P. aeruginosa in overnight culture Negative ND"
of TSB'
P. acruginosa-absorbed serume Positive ND
Rheumatoid factor-positive sera Negative ND
(n = 8)
"Specimens treated with 0.01 M 2-ME.
' Six negative blood culture supernatants were tested; the titers in two were
determined.
' A P. aeruginosa isolate recovered from the case patient was grown overnight
in trypticase soy broth (TSB) and was tested for reactivity.
"ND, not determined.
'The case patient's sera were absorbed with a P. aeruginosa isolate recovered
from his blood.
were negative. Both pronase-treated and 2-ME-treated speci-
mens were positive by the Premier EIA. A variety of specimens
were tested by the CALAS LA assay to assess reactivity
following treatment with 2-ME. These results are presented in
Table 2.
The effects of treatment with 2-ME on serum and CSF
collected from patients confirmed to be positive for C. neofor-
mans by culture were evaluated. Titers were determined for 38
serum specimens obtained from 20 patients and for 21 CSF
specimens from 9 patients with and without 2-ME treatment.
The titers were identical for 35 serum specimens and all 21
CSF specimens. The titers for the other three serum specimens
were within I dilution of those for the untreated serum
specimens.
The prevalence of false LAT positivity in sera from an
HIV-infected population of subjects was also examined. One
hundred serum specimens from HIV-positive patients with no
previous history of cryptococcal meningitis were tested for
their reactivities with the CALAS LA reagents. Of these, three
specimens were positive (titers, 20, 40, and 80). The specimen
with a titer of 20 remained reactive at that titer following 2-ME
treatment. However, the reactivities of the other two speci-
mens with the CALAS LA reagents were eliminated by 2-ME
treatment. Neither of the two patients from whom these two
serum specimens were obtained had clinical histories or labo-
ratory data consistent with a diagnosis of cryptococcosis during
the subsequent 12 months.
In an attempt to characterize the interfering factor, the case
patient's serum was absorbed with 10-fold serial dilutions of a
mouse monoclonal anti-cryptococcal capsular polysaccharide
antibody (Table 3). The "neutralized" sera were then tested
for their reactivities with cryptococcus antigen-coated latex
beads from the CALAS LA and CRYPTO-LEX LA assays.
The lowest dilutions of antibody (1:10, 1:100) were able to
absorb out or block the reactivity present in the serum when
tested by the CRYPTO-LEX LA assay. However, higher
dilutions (1:1,000, 1:10,000) did not block reactivity. In con-
trast, the CALAS LA assay demonstrated a strong agglutina-
tion reaction (4+) regardless of the absorbing antibody dilu-
tion.




dilution" CRYPTO LEX CALAS LA
LA assay assay
1:10 Negative Positive (4+)
1:100 Negative Positive (4+)
1:1000 Positive (2+) Positive (4+)
1:10,000 Positive (3+) Positive (4+)
"Mouse monoclonal anti-cryptococcal capsular polysaccharide antibody.
DISCUSSION
The detection of cryptococcal antigen in serum and/or CSF
by LA has become an essential laboratory tool in the diagnosis
of cryptococcal disease, particularly for HIV-infected individ-
uals (6, 8, 9, 12, 32). Most often, positive antigen tests correlate
with subsequently positive cultures. However, the cryptococcal
LAT is subject to false-positive results, particularly with serum
specimens (1, 31). Although the most common cause of this
phenomenon in serum is the presence of rheumatoid factor (1,
4, 10, 12, 17), cross-reactivity has also been associated with
malignancy (21, 30), chronic meningitis (24), collagen vascular
disease (1), agar syneresis fluid (5, 20), Capnocytophaga cani-
morsus (formerly DF-2) (33), and Tnichosporon beigelii (25-27).
Procedural modifications have been incorporated to alleviate
this problem, including pretreatment of specimens with heat
(16), EDTA (7, 12), pronase (17, 18, 32), dithiothreitol (16,
19), or 2-ME (30). In addition, many kits use latex beads
coated with normal rabbit globulin as a control reagent (1, 3,
10). However, false-positive LAT results accompanied by
negative results for reagent controls still occur at a low rate (1,
10, 15, 16).
In the present study, serum specimens collected on two
separate occasions from the patient described in the case
report yielded positive cryptococcal LAT results, despite sev-
eral negative fungal cultures. Culture of an abscess specimen
and one set of blood cultures were positive for P. aeruginosa,
and the patient responded to antibacterial therapy. Discussions
with the clinician concerning these results prompted the
laboratory to investigate the possibility of a false-positive LAT
result. The decision to pretreat specimens with 2-ME was
based on a previous study of Sachs et al. (30). They reported a
patient with squamous cell carcinoma of the lung who had a
positive titer for cryptococcal antigen in CSF but negative
cultures and India ink preparations. Treatment with 2-ME
eliminated the interfering substance, while pronase or dithio-
threitol treatment did not. The authors' hypothesis that the
patient's malignancy was responsible for the false-positive
LAT is consistent with previous reports (10, 21).
In our study pretreatment of the serum specimens with 0.01
M 2-ME eliminated reactivity with the antibody-coated latex
beads, thus confirming our suspicions of nonspecific cross-
reactivity. The 2-ME acts by reducing the disulfide bonds of
proteins (14, 29). Similar treatment of serum and CSF speci-
mens known to be positive for C. neoformans demonstrated no
loss of reactivity or significant decrease in titer. This assured us
that the 2-ME was not simply inactivating the latex reagent.
We observed that the interfering substance was not effectively
eliminated by 2-ME treatment in the Premier EIA. If the
cross-reactivity was due to an anti-idiotypic antibody molecule,
2-ME would abrogate lattice formation in a latex-based sys-
tem; however, Fab fragments might still be able to bind to the
capture antibody used in the EIA.
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The exact cause of the original cross-reactivity remains
undefined, although the role of the patient's P. aeruginosa
blood isolate appears to be negligible (Table 2). The cross-
reactivity can be characterized as being heat stable, pronase
resistant, and undetectable by normal rabbit globulin controls.
The results of the present study suggest that, in our patient
population, as many as 2% of HIV-infected individuals may
have positive cryptococcal LAT results in the absence of
disease. We demonstrated that this false-positive reactivity,
which is resistant to pronase, can be eliminated by treatment
with 2-ME. Our retrospective analysis of HIV-positive sera
detected one specimen that remained positive (titer, 1:20) even
after treatment with 2-ME. This may represent a true-positive
result; however, the patient was lost to follow-up.
Finally, the problem of cross-reactivity, particularly in LA
assays, highlights an important aspect of all diagnostic testing.
That is, laboratory information should be interpreted and used
only in the context of clinical information. Open lines of
communication between the clinician and laboratory personnel
are extremely important because they can identify those results
which seem questionable. Treatment of all serum specimens
with 2-ME would not be practical in a routine setting; however,
2-ME treatment of specimens with positive antigen titers in
high-risk patients without culture or histologic evidence of
cryptococcosis can help to detect those with false-positive
results. Close clinical follow-up of these patients is necessary
since the management of these patients remains unclear.
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